晚发型银屑病患者脆性骨折风险:一项英国人群研究
银屑病患者骨折绝对发生率为每万人年58例,对照组为每万人年53例;银屑病患者骨折风险较匹配对照增加10%(HR=1.10;95%CI 1.04,1.16)。使用甲氨蝶呤与骨折风险增加无关(HR=0.91;95%CI 0.72,1.15)。
要点
- 晚发型银屑病患者骨折风险较匹配对照增加10%(HR=1.10;95%CI 1.04,1.16)。
- 银屑病患者骨折绝对发生率为每万人年58例(95%CI 55,61),对照组为每万人年53例(95%CI 52,54)。
- 使用甲氨蝶呤与骨折风险增加无关(HR=0.91;95%CI 0.72,1.15)。
核心结论
- 识别与骨折风险增加相关的其他临床因素对改善骨折风险分层很重要。
- 需进一步研究以确定银屑病发病年龄与骨折风险之间的关系、探索病因解释,并明确现有骨折风险分层工具是否低估了银屑病患者的骨折风险。
研究设计与样本
- 采用英国临床实践研究数据链初级保健记录的队列研究。
- 识别1990至2004年新诊断银屑病的40岁及以上患者,随访至2015年。
- 每例暴露者随机选取最多4例按年龄、性别和诊所匹配的对照。
- 计算脆性骨折(髋部、椎体、脊柱、桡骨或未特指部位)每万人年发生率,并使用Cox回归模型比较风险率。
- 在暴露组内比较接受与未接受甲氨蝶呤患者的骨折风险。
主要发现
- 银屑病患者骨折绝对发生率为每万人年58例(95%CI 55,61),匹配对照为每万人年53例(95%CI 52,54)。
- 银屑病患者骨折风险较匹配对照增加10%(HR=1.10;95%CI 1.04,1.16)。
- 使用甲氨蝶呤与骨折风险增加无关(HR=0.91;95%CI 0.72,1.15)。
局限性
- 需进一步研究以确定银屑病发病年龄与骨折风险之间的关系、探索病因解释,并明确现有骨折风险分层工具是否低估了银屑病患者的骨折风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study aimed to examine fracture risk in patients with late-onset psoriasis. A cohort study was conducted using primary care records from the Clinical Practice Research Datalink. Psoriasis patients had a 10% increased risk of fracture compared to matched controls (hazard ratio (HR) = 1.10; 95% confidence interval (CI) 1.04, 1.16). INTRODUCTION: This study aimed to examine fracture risk in patients with late-onset psoriasis and investigate the effect of methotrexate on fracture risk. METHODS: A cohort study was conducted using primary care records from the UK-based Clinical Practice Research Datalink. Individuals aged 40 years and over, with incident (new onset) diagnoses of psoriasis, were identified from 1990 to 2004 and followed up until 2015. For each exposed individual, up to four age-, gender-, and practice-matched controls were randomly selected. Incidence rates of fragility fracture (hip, vertebral, spine, radius or unspecified site) per 10,000 person-years were calculated and hazard rates were compared to the unexposed using Cox regression models. The risk of fracture was also estimated, within the exposed group for patients receiving/not receiving methotrexate. RESULTS: Twenty-four thousand two hundred nineteen patients with psoriasis and 94,820 controls were identified. The absolute rate of fracture in psoriasis patients was 58 per 10,000 person-years (95% CI 55, 61) and 53 per 10,000 person-years in the matched controls (CI 52, 54). Psoriasis patients had a 10% increased risk of fracture compared to their matched controls (HR = 1.10; 95% CI 1.04, 1.16). Methotrexate use was not associated with increased risk (HR = 0.91; 95% CI 0.72, 1.15). CONCLUSIONS: Identifying additional clinical factors associated with increased fracture risk is important in improving fracture risk stratification. Further work is needed to determine the relationship between age of onset of psoriasis and fracture risk, explore causative explanations, and identify if existing fracture risk stratification tools underestimate fracture risk in patients with psoriasis.
引用
- Paskins Z, Whittle R, Abdul Sultan A, et al. Risk of fragility fracture among patients with late-onset psoriasis: a UK population-based study. Osteoporos Int. 2018. PMID: 29574516. doi:10.1007/s00198-018-4491-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。